Bank of America Securities: Maintaining JD Health's (06618) Target Price of HK$57 and “Buy” Rating

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Bank of America Securities released a research report saying that JD Health (06618)'s operations fluctuated in the third quarter, but structural growth was still intact. The company's third-quarter revenue increased 17% year over year, better than expected, and improved from 15% in the second quarter. The bank reaffirmed its “buy” rating and maintained a target price of HK$57.

The bank still believes that JD Health's profits are resilient and can benefit from economies of scale, supply chain efficiency, pharmaceutical profit margins and operational efficiency, and profit margins are expected to continue to expand. The bank also slightly lowered its 2026 earnings forecast per share from RMB 2.17 to RMB 2.16, and slightly raised its 2027 earnings forecast per share from RMB 2.51 to RMB 2.52.